In patients with rheumatoid arthritis, N-acylethanolamine anandamide (AEA), a dual inhibitor of fatty acid amide hydrolase/cyclooxygenase-2 (FAAH/COX-2), demonstrated the ability to inhibit MAPK signaling. This evidence concerns the gene FAAH and rheumatoid arthritis.